Abstract
Vaccination is one of the most vigorous ways to intervene in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Cases of autoimmune hepatitis (AIH) after coronavirus disease (COVID-19) vaccination have been increasingly reported. Twenty-seven cases of AIH are summarized in this study, providing emerging evidence of autoimmune reactions in response to various COVID-19 vaccines, including in patients with special disease backgrounds such as primary sclerosing cholangitis (PSC), liver transplantation, and previous hepatitis C virus (HCV) treatment. Molecular mimicry, adjuvants, epitope spreading, bystander activation, X chromosome, and sceptical hepatotropism of SARS-CoV-2 may account for, to some extent, such autoimmune phenomena. Immunosuppressive corticosteroids perform well with or without azathioprine in such post-COVID-19-vaccination AIH. However, determination of the exact mechanism and establishment of causality require further confirmation.
Introduction
While COVID-19 vaccines have been instrumental in controlling the global pandemic, rare immune-mediated adverse events have emerged. Autoimmune hepatitis (AIH)—a condition where the body’s immune system mistakenly attacks liver cells—is one such event. The relationship between specific vaccine platforms and liver-related autoimmune phenomena has remained complex. This study aggregates 27 clinical cases to provide a clearer clinical picture, exploring biochemical manifestations, histological traits, and potential biological triggers.
Clinical Characteristics and Methodology
The authors conducted a systematic review of literature published between 2021 and 2022, identifying 27 documented cases of post-vaccination AIH. The analysis focused on patient demographics, vaccine specifics (type and dose), clinical presentation (latency and symptoms), and diagnostic rigor using standardized AIH scoring systems. Histological reviews sought hallmark traits such as rosette formation and interface hepatitis.
Key Results
The study found that AIH onset was platform-agnostic, occurring after mRNA (Moderna, Pfizer), adenovirus vector (AstraZeneca), and inactivated virus (CoronaVac) vaccinations. This suggests the trigger may be the immune response to the spike protein itself rather than a specific delivery vehicle.
- Latency and Severity: Symptoms typically appeared between 1 and 31 days post-vaccination. Patients exhibited significant biochemical markers of liver distress, with Alanine aminotransferase (ALT) levels reaching as high as 2029 U/L.
- Demographics: A notable female predisposition was observed, with 22 of the 27 cases being female. This may be linked to the X chromosome's role in carrying immune-related genes and the stimulatory effects of estrogen.
- Treatment Outcomes: Immunosuppressive therapy, primarily corticosteroids (prednisone/prednisolone), proved highly effective. Of the 27 patients, 25 recovered, while two deaths were recorded due to complications or external constraints.
Proposed Mechanisms
Several biological theories may explain these occurrences:
- Molecular Mimicry: Structural similarities between the SARS-CoV-2 spike protein and human proteins may lead the immune system to cross-react with liver antigens.
- Adjuvants (ASIA): Vaccine components, such as lipid nanoparticles, may trigger Autoimmune/Inflammatory Syndrome Induced by Adjuvants.
- Bystander Activation: The intense immune surge following vaccination might reactivate dormant, pre-existing autoreactive T-cells.
Conclusion
While the correlation between COVID-19 vaccination and AIH is evident in these cases, the authors emphasize that correlation does not equal causation. Vaccination may simply unmask pre-existing, undiagnosed conditions. Ultimately, the benefits of vaccination in preventing severe COVID-19 far outweigh the risks of these rare events. Clinicians are encouraged to remain vigilant for signs of liver dysfunction following vaccination to ensure timely intervention.
Summary updated